About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

Patients with colon cancer who still have cancer cells in their blood after surgery may improve their survival odds with ...

Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of ≥10 months in the FRESCO-2 study. Updated analysis of ...

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...

A new study has found that taking a small daily dose of aspirin could help stop colon cancer from returning in some patients.

Diet Is Main Risk Factor for Colon Cancer in Younger Adults, New Study Suggests Aug. 14, 2024 — A new study has identified diet-derived molecules called metabolites as main drivers of young ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

Patients who had positive ctDNA tests after surgery were almost twice as likely to be alive at 3 years if they received ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...

Cancer is treated with multiple modalities simultaneously, such as surgery, chemotherapy, and radiation therapy.